THE WELINK.CARE LABEL HAS BEEN AWARDED TO

Axelife

ON THE 18TH OF SEPTEMBER 2024

WITH THE HIGH DISRUPTION SCORE OF 69 %

WeLink.Care Label

Dr. Thierry Vermeeren, CEO

The WeLink.Care label uses a composite index scoring the disruption value of a digital solution use case in the daily health practice.
Our expert team has reviewed the preselected digital solution with a set of 35 points of measure, based on interviews, documents research and analysis.

AXELIFE RECEIVES THE WELINK.CARE LABEL

Introduction

Axelife has been honored with the WeLink.Care Label, recognizing its innovative contributions to digital health. This distinction underscores Axelife's commitment to advancing cardiovascular risk assessment through its non-invasive medical device, pOpmètre®.

About the WeLink.Care Label

Established in 2020 during the onset of the COVID-19 pandemic, the WeLink.Care Label was created to contribute to the international effort to fight the pandemic. It has since evolved into a comprehensive certification system that identifies and promotes impactful digital health solutions globally. The label is managed by a Belgian-based team of experts led by an international scientific committee.

The WeLink.Care Label serves as a trusted benchmark for investors and healthcare institutions seeking to identify innovative eHealth solutions. By providing a library of technological use cases covering the entire spectrum of the health continuum, it addresses the need for disruption in healthcare. This certification attests to the quality and impact of digital health solutions, guiding stakeholders in making informed decisions.

The Evaluation Process

The evaluation process for the WeLink.Care Label is rigorous and multi-faceted, ensuring that only solutions with significant potential to transform healthcare are certified. It begins with a comprehensive assessment of the solution's innovation, examining how it leverages technology to address current healthcare challenges. This includes an analysis of the solution's uniqueness, scalability, and applicability across different healthcare settings.

Following the innovation assessment, the process delves into the solution's impact on healthcare delivery. This involves evaluating clinical outcomes, patient engagement, and the potential to improve efficiency within healthcare systems. The evaluation team reviews data from clinical trials, user testimonials, and case studies to substantiate the solution's effectiveness and benefits.

The third phase focuses on compliance and interoperability. The solution is examined for adherence to international healthcare standards, data privacy regulations, and its ability to integrate seamlessly with existing healthcare infrastructures. This ensures that the solution not only meets regulatory requirements but also supports the continuity and coordination of care.

Finally, the evaluation considers the sustainability and business model of the solution. This includes an analysis of the company's financial health, market strategy, and the potential for long-term viability. The goal is to ensure that certified solutions are not only innovative and effective but also capable of sustaining operations and scaling to meet the demands of the healthcare industry. By adhering to this thorough evaluation process, the WeLink.Care Label ensures that certified solutions like Axelife's pOpmètre® are well-positioned to make a meaningful impact on global healthcare.

AXELIFE

Introduction to the company

Founded in 2010, Axelife is a French medtech company specializing in cardiovascular health assessment through innovative, non-invasive technology. The company was established by a physician passionate about biotechnology and preventive cardiology, aiming to develop new tools for assessing arterial stiffness—an independent risk factor for cardiovascular disease. Over the years, Axelife has evolved into a leader in pulse wave analysis, leveraging its expertise in biomedical signal processing to provide cutting-edge solutions for healthcare professionals. The company collaborates with leading researchers and institutions to refine its technology and expand its applications. Today, Axelife's solutions research facilities across multiple countries.

The Solution

Axelife's flagship solution, the pOpmètre®, is a non-invasive medical device designed to assess arterial stiffness, a key indicator of cardiovascular health. Unlike traditional methods that require complex procedures and trained operators, pOpmètre® offers a simple and quick measurement process using photoplethysmography (PPG) technology. By analyzing pulse wave velocity, the device provides healthcare professionals with valuable insights into a patient's arterial health, enabling early detection of cardiovascular risks. The pOpmètre® is designed for widespread use in both clinical and preventive settings. It allows general practitioners, cardiologists, and other healthcare providers to integrate arterial stiffness assessment into routine check-ups without requiring specialized training. By making advanced cardiovascular diagnostics more accessible, Axelife empowers healthcare professionals to adopt a proactive approach to cardiovascular disease prevention and management.

Features and Benefits

Axelife's pOpmètre® stands out for its ease of use and rapid measurement process. The device requires only two accessible extremities—typically a finger and a toe—to capture arterial pulse wave data. Unlike traditional tonometry-based systems that depend on precise operator technique, pOpmètre® is user-friendly and delivers highly reproducible results. The entire measurement process takes just a few minutes, making it a practical tool for routine clinical assessments. Beyond its simplicity, pOpmètre® delivers actionable insights by translating arterial stiffness data into an "arterial age" metric. This feature enhances patient understanding of cardiovascular risks, encouraging lifestyle modifications and adherence to preventive care. By integrating seamlessly into clinical workflows, the device aids in risk stratification, therapy adjustments, and long-term cardiovascular health monitoring.

Compliance and Future Outlook

Axelife has obtained CE certification for its pOpmètre®, ensuring compliance with European regulatory standards for medical devices. The company is actively working towards FDA approval to expand into the U.S. market, where cardiovascular disease remains a leading health concern. Additionally, Axelife continues to refine its technology and explore new applications, including potential uses in neurology and sleep medicine. With growing interest in arterial stiffness as a critical health marker, Axelife is well-positioned for international growth and continued innovation in cardiovascular diagnostics.

DISRUPTION SCORE

Axelife's pOpmètre® presents a high disruption potential in cardiovascular diagnostics. Its speed, ease of use, and operator-independent design enable task delegation to nurses and medical staff, enhancing workflow efficiency. The device's strong reproducibility further supports its reliability. However, broader adoption requires additional peer-reviewed studies to solidify its clinical value and encourage physician trust. Strengthening scientific validation will be key to positioning pOpmètre® as a transformative tool in preventive cardiology.

BUSINESS PERFORMANCE

|~ average ~|

CHANGE OF PRACTICES



|~ very significant ~|

DISRUPTION POTENTIAL



|~ high ~|

SOLUTION MATURITY



|~ medium ~|

USER EXPERIENCE

|~ very good ~|

BUSINESS MODEL

Axelife's business model is developing but faces structural challenges. While the company owns the intellectual property for its pOpmètre® and benefits from a reliable national private investor, its financial sustainability remains uncertain, with expenditures still exceeding revenue. The management team lacks key roles in medical direction, sales, and technical leadership. Additionally, reliance on distributors limits visibility on customer acquisition costs and retention rates, making strategic market positioning and revenue growth more complex.

BUSINESS MODEL

|~ average ~|

BUSINESS PERFORMANCE



|~ average ~|

COMMERCIAL READINESS LEVEL

|~ first sales ~|

SOLUTION MATURITY

Axelife's pOpmètre® demonstrates moderate solution maturity. While it has been showcased at conferences and is used in a few clinical settings, comprehensive scientific studies, including PREMS and PROMS, have yet to be published. Development is supported by a Paris hospital, reinforcing its medical relevance. The device is commercially deployed in France, the Netherlands, Italy, North Africa, and the Middle East, but further clinical validation is needed to strengthen its credibility and broader adoption.



CHANGE OF PRACTICES

Axelife's pOpmètre® has a significant impact on clinical practices by enabling standardized, non-operator-dependent measurements of arterial stiffness. The biomarkers it assesses are scientifically validated, and proper training ensures result consistency. With CE marking and ongoing FDA certification, the device meets regulatory standards. However, while physicians can generate PDFs for patient records, the lack of direct data transfer or interoperability limits seamless integration into existing healthcare information systems.



|~ 5 relevant measure points ~|



|~ very significant ~|

USER EXPERIENCE : THE PROFESSIONAL AND PATIENT PERSPECTIVE

Axelife's pOpmètre® is well-accepted by healthcare professionals, supporting prediction, prevention, and follow-up in cardiovascular care. Its ease of use and non-invasive design make it accessible, though proper training is essential for measurement reliability. While the device adapts to different languages, its lack of network-based data transfer limits interoperability with digital health systems. Enhancing data integration capabilities could further improve usability and workflow efficiency in clinical settings.



LINKS AND RESOURCES

https://www.axelife.com/

https://label.welink.care/

This report is based on the information provided by the scored company, input from various stakeholders, and the application of the WeLink.Care© methodology by OZConsulting. The findings, scores, and evaluations presented are intended solely for informational purposes and do not constitute a guarantee or endorsement of the quality, effectiveness, or commercial viability of the evaluated digital health solution.

The conclusions are drawn from the data available at the time of the study and may not reflect subsequent changes. OZConsulting assumes no responsibility for the accuracy or completeness of the information provided by the scored company or any third parties involved. Any reliance on this report is at the reader's own risk.
